Related references
Note: Only part of the references are listed.Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial
Liselotte M. S. Boeve et al.
EUROPEAN UROLOGY (2019)
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Piet Ost et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases
Giuseppe Fanetti et al.
MEDICAL ONCOLOGY (2018)
Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study
Rosario Mazzola et al.
MEDICAL ONCOLOGY (2018)
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
Christopher C. Parker et al.
LANCET (2018)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
Philip Cornford et al.
EUROPEAN UROLOGY (2017)
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA
Stephane Oudard et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy
Aurelie De Bruycker et al.
BJU INTERNATIONAL (2017)
Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy
Elisabetta Ponti et al.
EUROPEAN UROLOGY FOCUS (2017)
Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study
Luca Triggiani et al.
BRITISH JOURNAL OF CANCER (2017)
Stereotactic Body Radiotherapy for Oligometastasis: Opportunities for Biology to Guide Clinical Management
Rohann J. M. Correa et al.
CANCER JOURNAL (2016)
Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences
P. Ost et al.
CLINICAL ONCOLOGY (2016)
Impact of 18F-Choline PET/CT in the Decision-Making Strategy of Treatment Volumes in Definitive Prostate Cancer Volumetric Modulated Radiation Therapy
Filippo Alongi et al.
CLINICAL NUCLEAR MEDICINE (2015)
Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the Literature
Piet Ost et al.
EUROPEAN UROLOGY (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
Choline-PET in prostate cancer management: The point of view of the radiation oncologist
Berardino De Bari et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
Karel Decaestecker et al.
RADIATION ONCOLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
David A. Palma et al.
BMC CANCER (2012)
ROBOTIC IMAGE-GUIDED STEREOTACTIC RADIOTHERAPY, FOR ISOLATED RECURRENT PRIMARY, LYMPH NODE OR METASTATIC PROSTATE CANCER
Barbara Alicja Jereczek-Fossa et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi et al.
LANCET ONCOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Richard L. Wahl et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
William P. Harris et al.
NATURE CLINICAL PRACTICE UROLOGY (2009)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
